Vimarsana
Biggest News Aggregation in the World

Page 10 - Diffuse Largeb Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diffuse Largeb Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diffuse Largeb Cell Today - Breaking & Trending Today

MorphoSys : National Comprehensive Cancer Network® Updates Designation of Monjuvi® (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas - Form 6-K - Vimarsana News

MorphoSys : National Comprehensive Cancer Network® Updates Designation of Monjuvi® (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas - Form 6-K

National Comprehensive Cancer Network® Updates Designation of Monjuvi® to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas BOSTON,... | March 15, 2022

AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021 - Vimarsana News

AstraZeneca advances ambition to redefine care for blood cancer at ASH 2021

AstraZeneca will present new data underscoring its commitment to transforming haematologic cancer care at the 63rd American Society of Hematology

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring - Vimarsana News

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring

Maternal Omega 3-rich diet may reduce onset of breast cancer in offspring According to researchers at Marshall University, a maternal diet rich in Omega-3 fatty acids protects from breast cancer development in offspring. In a new study recently published by Frontiers in Cell and Developmental Biology, researchers noted a significant difference in mice from mothers that were fed a diet rich in canola oil, compared with mothers fed a diet rich in corn oil. A maternal Omega 3-rich diet affected genome-wide epigenetic landscape changes in offspring and potentially modulated gene expression patte...

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab - Vimarsana News

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab

frontMIND Study Evaluating Tafasitamab Combination as a  First-line Treatment for Diffuse Large B-Cell Lymphoma PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell ly...

University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy - Vimarsana News

University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy

University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy University Hospitals offering new cancer treatment for patients and last updated 2021-05-08 10:11:56-04 CLEVELAND — When 61-year-old Ken Anderson was diagnosed with Multiple Myeloma 3 years ago, he didn’t know what to expect. “It kind of hits you. It hits you hard,” he said. “It’s a blood cancer, and it’s in your bone marrow, and it degenerates your bones is what it does.” The cancer is incurable, but treatable. “You live with it and you have to have many ro...